A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 11, 2012, Pages 1391-1398

  Fury, Matthew G ^a   Sherman, Eric ^a   Lisa, Donna ^a   Agarwal, Neeraj ^b   Algazy, Kenneth ^c   Brockstein, Bruce ^d   Langer, Corey ^c   Lim, Dean ^e   Mehra, Ranee ^f   Rajan, Sandeep K ^g   Korte, Susan ^a   Lipson, Brynna ^a   Yunus, Furhan ^h   Tanvetyanon, Tawee ⁱ   Smith Marrone, Stephanie ^a   Ng, Kenneth ^a   Xiao, Han ^a   Haque, Sofia ^a   Pfister, David G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^h UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; DESQUAMATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FAINTNESS; FATIGUE; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEADACHE; HUMAN; HYPOMAGNESEMIA; LARYNX; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH CAVITY; MULTICENTER STUDY; MUSCLE WEAKNESS; NAIL DISEASE; NAUSEA; OVERALL SURVIVAL; PRIMARY TUMOR; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE; VOMITING;

EID: 84871414072     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0144     Document Type: Article

References (22)

1. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-7356. (Pubitemid 36025259)
2. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-832. (Pubitemid 28280548)
3. Sharafinski ME, Ferris RL, Ferrone S, Grandis JR. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 2010;32:1412-1421.
4. Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7:301-311. (Pubitemid 40544648)
5. Specenier P, Vermorken JB. Cetuximab in the treatment of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther 2011;11:511-524.
6. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-5577.
7. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based chemotherapy. J Clin Oncol 2007;25:2171-2177. (Pubitemid 46954639)
8. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer. J Clin Oncol 2005;23:8646-8654. (Pubitemid 46211507)
9. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. New Engl J Med 2008;359:1116-1127.
10. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-914. (Pubitemid 30106623)
11. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001;7:1204-1213. (Pubitemid 32708671)
12. Tabernero J, Ciardiello F, Rivera F, et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose escalation cetuximab. Ann Oncol 2010;21:1537-1545.
13. Tabernero J, Pfeiffer P, Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist 2008;13:113-119. (Pubitemid 351342574)
14. Tabernero J, Cervantes A, Rivera F, et al. Pharmacogenomic and pharmacogenetic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of phase I dose escalation study. J Clin Oncol 2010;28:1181-1189.
15. Martin-Martorelli P, Rosello S, Rodriguez-Braun E, et al. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer 2008;99:455-458.
16. Pfeiffer P, Nielsen D, Bjerregaard J, et al. Biweekly cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin, and 5-fluorouracil. Ann Oncol 2008;19:1141-1145. (Pubitemid 351796340)
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
18. Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:2659-2665. (Pubitemid 46622087)
19. Bouchahda M, Macarulla T, Liedo G, et al. Feasibility of cetuximab given wtih a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Med Oncol 2011;28(Suppl 1):S253-258.
20. Vidal L, Gillison ML. Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol Oncol Clin N Am 2008;22:1125-1142.
21. Schoennemann KR, Bjerregaard JK, Hansen TP, et al. Biweeky cetuximab and irinotecan as second line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer 2011;14:219-225.
22. Pfeiffer P, Nielsen D, Bjerregaard J, et al. Biweekly cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin, and 5-fluorouracil. Ann Oncol 2008;19:1141-1145. (Pubitemid 351796340)